Paid Clinical Trials and Focus Groups by Location |
|
|
|
Conditions: Haemophilus Influenzae Type B Related Disease; Pneumonia; Meningitis; Cellulitis; Osteomyelitis; Epiglottis
Interventions: Biological: InfanrixTM; Biological: GSK Biologicals' Haemophilus inluenzae type b vaccine (GSK 208108); Biological: ActHIBTM; Biological: PentacelTM; Biological: PediarixTM; Biological: PrevnarTM; Biological: RotarixTM; Biological: EngerixTM-B
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Condition: Severe Nodular Acne
Intervention: Drug: CIP-Isotretinoin and Isotretinoin
Sponsor: Cipher Pharmaceuticals Inc.
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Ischemia
Interventions: Other: BMS747158; Other: BMS747158
Sponsor: Lantheus Medical Imaging
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Moderate Risk of CVD
Interventions: Drug: Aspirin (Acetylsalicylic acid, BAYE4465); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: duloxetine hydrochloride; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Other: internet-based intervention; Procedure: assessment of therapy complications
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastatic Cancer
Intervention: Drug: dasatinib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: lapatinib ditosylate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: atrasentan hydrochloride; Drug: docetaxel; Drug: prednisone; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Drug: cisplatin; Drug: etoposide; Drug: gemcitabine hydrochloride; Drug: methylprednisolone
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Pain
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Trans Tasman Radiation Oncology Group at Calvary Mater Newcastle
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; International Breast Cancer Study Group; Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009